Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 March 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Natural history of liver fibrosis in hepatitis C virus infection

Researchers from England and France find that demographic features account for a minority of fibrosis rate variability.

News image

fiogf49gjkf04

The rate of development of liver fibrosis in hepatitis C virus (HCV) infection varies between individuals.

In this study, researchers determined whether fibrosis progresses linearly through the grading scales. They also identified factors influencing the rate of fibrosis.

The team’s findings are published in the April issue of Gut.

The researchers identified 917 HCV infected patients, who had undergone at least 1 liver biopsy.

They scored the biopsies were scored using the modified HAI (Ishak) and METAVIR systems. These 2 systems were compared.

Male sex, older age at infection, and viral genotype are associated with more rapid fibrosis progression.
Gut

All patients were treatment naïve at first biopsy.

Researchers examined demographic features for their relationship to fibrosis rate using univariate and multivariate analysis.

In addition, a subgroup of patients who had 2 biopsies was examined to test the assumption that fibrosis progresses in a linear fashion.

The research team found that male sex, older age at infection, and viral genotype non-1 were all associated with a rapid rate of fibrosis. Using multiple linear regression, they determined that these factors accounted for 30% of the variability in fibrosis rate.

The team also found that the METAVIR and Ishak scores were highly correlated.

However, in the 137 patients who had 2 biopsies, the predicted probability for an increase of 1 on the fibrosis score was too low to assess linearity.

Dr Wright’s team concluded, “Demographic features account for a minority of fibrosis rate variability”.

“The Ishak and METAVIR scoring systems are equivalent.”

“Linearity of fibrosis progression cannot be assessed in biopsies only a few years apart.”

Gut 2003; 52: 574-9
13 March 2003

Go to top of page Email this page Email this page to a colleague

 24 March 2017 
Prevalence of undiagnosed celiac disease
 24 March 2017 
MRI for local staging of colon cancer
 24 March 2017 
In-office communication about ulcerative colitis
 23 March 2017 
H. pylori and GERD in children
 23 March 2017 
Prespectives on the management of fecal incontinence
 23 March 2017 
Suspected nonceliac gluten sensitivity
 22 March 2017 
Abdominal visceral fat and new erosive esophagitis
 22 March 2017 
Role of microbiota in colorectal surgery
 22 March 2017 
Disease activity in eosinophilic esophagitis
 21 March 2017 
Hepatitis C virus–related hepatic myelopathy
 21 March 2017 
Global trends in colorectal cancer mortality
 21 March 2017 
Pain in pancreatic cancer
 20 March 2017 
Metastasis in human colorectal cancer
 20 March 2017 
Fistula treatment of Crohn’s disease
 20 March 2017 
NASH treatment and MRI
 17 March 2017 
Acute liver failure in Scotland
 17 March 2017 
Microbiota in colorectal cancer 
 17 March 2017 
Among Persons with IBD
 16 March 2017 
Hepatocellular carcinoma risk in different etiologies of cirrhosis
 16 March 2017 
IBD disability index
 16 March 2017 
Transition readiness scores in adolescents with IBD
 15 March 2017 
European consensus on fecal microbiota transplantation 
 15 March 2017 
Hepatocellular carcinoma in the USA 
 15 March 2017 
Hospital readmission for ulcerative colitis
 14 March 2017 
Cardiovascular diseases risk in Barrett's
 14 March 2017 
Assessment of competence in colonoscopy
 14 March 2017 
Cholecystectomy to prevent recurrent pancreatitis
 13 March 2017 
Gallstone disease after colectomy for ulcerative colitis
 13 March 2017 
Achalasia in Chicago since high-resolution manometry
 13 March 2017 
Vedolizumab exposure in pregnancy
 10 March 2017 
Thiopurine therapy in IBD
 10 March 2017 
Complications in advanced fibrosis in Hep C eradication
 10 March 2017 
Intragastric balloons for obesity-related co-morbidities
 09 March 2017 
Intestinal tuberculosis vs Crohn's disease
 09 March 2017 
Predictors of relapse in children with IBD
 09 March 2017 
Direct-acting antiviral regimen for Hep C genotype 3 
 08 March 2017 
Sterile fecal filtrate transfer for C. diff
 08 March 2017 
Drug-induced liver injury
 08 March 2017 
Pharmacotherapy for alcohol dependence
 07 March 2017 
Psychotropic drugs in functional dyspepsia
 07 March 2017 
Vagus nerve and appetite regulation
 07 March 2017 
Gastrointestinal involvement in systemic sclerosis
 06 March 2017 
Small bowel abnormalities in IBS 
 06 March 2017 
Treatment response in NASH with MRI
 06 March 2017 
Intestinal bacterial overgrowth and PPIs in children
 03 March 2017 
Alcohol and risk of gallstone disease
 03 March 2017 
Smoking at colon cancer diagnosis influences survival
 03 March 2017 
Improvements in Crohn’s Disease outcomes over time
 02 March 2017 
Surviving sepsis guidelines
 02 March 2017 
Tenofovir and Hep B transmission in pregnancy
 02 March 2017 
Diagnosis of pediatric IBD 
 01 March 2017 
Healthcare utilization amonth IBD Veterans
 01 March 2017 
Complications after ileocecal resection in Crohn’s
 01 March 2017 
Fecal microbiotica transplnantation

 28 February 2017 
Smoking and cancer-specific survival in colon cancer
 28 February 2017 
ALT levels and all-cause mortality
 28 February 2017 
American Gastroenterological Association for acute liver failure
 27 February 2017 
Hep B cure research
 27 February 2017 
Elemental diet in adult eosinophilic esophagitis patients
 27 February 2017 
Eluxadoline in IBS-diarrhea

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us